Schaffhausen, Switzerland-based Garmin Ltd. (GRMN) designs, develops, manufactures, markets, and distributes a range of wireless devices. Valued at $41.3 billion by market cap, the company designs, develops, manufactures, and markets hand-held, portable, and fixed mount GPS-enabled products serving automotive, aviation, marine, outdoor, and fitness markets. Shares of this leading provider of navigation and communication devices have underperformed the broader market over the past year. GRMN has gained 2. ...

Core Viewpoint - Mohawk Industries is a significant player in the textile and home furnishing industry, maintaining a Neutral rating from UBS while showing resilience in earnings performance despite a slight revenue miss [1][3]. Group 1: Stock Performance - UBS has maintained a Neutral rating for Mohawk Industries, advising investors to hold the stock priced at $132.60 [1]. - The price target for Mohawk Industries has been raised from $134 to $140, reflecting a positive outlook despite a current stock price decrease of 0.66% [2]. - The stock has traded between $131.14 and $139.11, with a market capitalization of approximately $8.24 billion [2]. Group 2: Earnings and Revenue - Mohawk Industries reported quarterly earnings of $2 per share, surpassing the Zacks Consensus Estimate of $1.98, indicating an earnings surprise of +0.92% compared to the previous year's $1.95 per share [3]. - The company reported revenues of $2.7 billion, slightly below the Zacks Consensus Estimate by 0.72%, but this represents a slight increase from $2.64 billion reported in the same quarter the previous year [3][4]. - Mohawk Industries has exceeded consensus EPS estimates three times in the past four quarters, demonstrating resilience in its earnings performance [4]. Group 3: Volatility and Market Range - The stock's 52-week range has seen a high of $143.13 and a low of $96.24, indicating some volatility in its performance [4].

Core Insights - Airbnb, Inc. (ABNB) has experienced an approximate 18% decline in stock value since being downgraded to a hold rating in February 2024 [1] Company Overview - The article reflects on the performance of ABNB stock over the past two years, indicating a significant loss in value [1] Analyst Background - Dilantha De Silva, the author, is an experienced equity analyst with over 10 years in the investment industry, focusing on small-cap stocks often overlooked by Wall Street [1] - He is a CFA Level III candidate and holds qualifications from the Chartered Institute for Securities and Investment (CISI) [1] - Dilantha has been featured on major financial platforms such as CNBC, Bloomberg, Nasdaq, and Yahoo Finance [1]

Core Insights - Northrop Grumman Corporation (NOC) has a market capitalization of $99.7 billion and is a leading aerospace and defense technology company based in Falls Church, Virginia [1] - Over the past 52 weeks, NOC shares have increased by 54.4%, significantly outperforming the S&P 500 Index, which gained 11.8% during the same period [1] - Year-to-date, NOC's stock is up 23.2%, while the S&P 500 Index has experienced a slight decline [1] Performance Comparison - NOC has underperformed compared to the State Street SPDR S&P Aerospace & Defense ETF (XAR), which rose by 59.2% over the past 52 weeks, although NOC outperformed XAR's 12.2% year-to-date increase [2] Financial Results - On January 27, NOC shares rose by 2.7% following stronger-than-expected Q4 results, with net sales increasing by 9.6% year-over-year to $11.7 billion, slightly exceeding consensus estimates [3] - The company's adjusted EPS reached $7.23, reflecting a 13.1% increase from the previous year and surpassing analyst expectations by 3.3% [3] Future Earnings Expectations - For fiscal 2026, analysts project NOC's EPS to grow by 6.5% year-over-year to $28.05, with a mixed earnings surprise history where the company exceeded estimates in three of the last four quarters [4] - The consensus rating among 22 analysts is a "Moderate Buy," consisting of 11 "Strong Buy," one "Moderate Buy," and 10 "Hold" ratings [4] Analyst Ratings and Price Targets - The current analyst configuration is less bullish than two months ago, with 12 analysts suggesting a "Strong Buy" rating [5] - Argus has maintained a "Buy" rating on NOC and raised its price target to $785, indicating an 11.7% potential upside from current levels [5] - The mean price target is $732.45, representing a 4.3% premium, while the highest price target of $815 suggests a 16% potential upside [5]

Core Insights - The article emphasizes the importance of utilizing Zacks Premium and its various tools to enhance investment confidence and market opportunities for both new and seasoned investors [1]. Zacks Style Scores - Zacks Style Scores provide a unique rating system for stocks based on value, growth, and momentum characteristics, serving as complementary indicators to the Zacks Rank [2]. - Each stock is rated from A to F, with A indicating the highest potential for outperforming the market [3]. Value Score - The Value Style Score identifies attractive and discounted stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3]. Growth Score - The Growth Style Score focuses on a company's future prospects by analyzing projected and historical earnings, sales, and cash flow to identify stocks with sustainable growth [4]. Momentum Score - The Momentum Style Score helps investors capitalize on price trends, using metrics like one-week price changes and monthly earnings estimate changes [5]. VGM Score - The VGM Score combines the three Style Scores to identify stocks with the best value, growth forecasts, and momentum, making it a strong indicator alongside the Zacks Rank [6]. Zacks Rank - The Zacks Rank is a proprietary stock-rating model that leverages earnings estimate revisions to assist investors in building successful portfolios [7]. - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [8]. Stock Selection Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 that also have Style Scores of A or B [9]. - Stocks with lower ranks (3 Hold, 4 Sell, 5 Strong Sell) should be approached cautiously, even if they have high Style Scores, due to potential downward earnings forecasts [10]. Company Spotlight: Yum China Holdings - Yum China Holdings, Inc. is rated 2 (Buy) on the Zacks Rank and has a VGM Score of A, indicating strong investment potential [11]. - The company is projected to achieve year-over-year earnings growth of 15.9% for the current fiscal year, with upward revisions in earnings estimates from analysts [12].

Company Overview - ArcelorMittal is the world's leading steel and mining company, operating in over 60 countries with a balanced portfolio of cost-competitive steel plants across both developed and developing markets [11] - The company is a leader in key sectors including automotive, household appliances, packaging, and construction [11] Investment Potential - ArcelorMittal has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating a solid investment profile [11] - The company is particularly appealing to growth investors, with a Growth Style Score of B and a forecasted year-over-year earnings growth of 28.3% for the current fiscal year [12] - Recent upward revisions in earnings estimates by two analysts over the last 60 days have increased the Zacks Consensus Estimate by $0.11 to $4.94 per share [12] - ArcelorMittal has an average earnings surprise of +26.6%, further enhancing its attractiveness to investors [12]

Company Overview - Solventum Corporation (SOLV) is an independent healthcare company founded in 2023, based in Minnesota, with a market capitalization of $14 billion. The company operates in three segments: Medsurg, Dental Solutions, and Health Information Systems [1]. Stock Performance - Over the past year, SOLV shares have underperformed the broader market, with an 8.3% increase over 52 weeks and a 1.5% rise year-to-date (YTD). In comparison, the S&P 500 Index has returned 14.4% over the past year and 1.4% in 2026 [2]. - SOLV has outperformed the State Street Healthcare Select Sector SPDR ETF (XLV), which rose 6.2% over the past 52 weeks [3]. Recent Developments - On November 20, SOLV shares rose 2.9% following the announcement of a definitive agreement to acquire Acera Surgical for $725 million in cash, plus up to $125 million in contingent cash payments. This acquisition is expected to strengthen SOLV's portfolio and boost investor confidence [6]. Earnings Expectations - For the current year ending December 2025, analysts expect SOLV's earnings per share (EPS) to decline by 10% year-over-year to $6.03 on a diluted basis. However, the company has a strong earnings surprise history, surpassing consensus estimates in the last four quarters [7]. - Among the 14 analysts covering SOLV stock, the consensus rating is a "Moderate Buy," consisting of seven "Strong Buy" ratings, six "Holds," and one "Strong Sell" [7]. Analyst Ratings - The stock has become more bullish over the past month, with the number of "Strong Buy" ratings increasing from five to seven [8]. - Keybanc analyst Brett Fishbin upgraded SOLV stock to an "Overweight" rating and set a new price target of $97 [8].

Core Viewpoint - Rollins, Inc. has demonstrated strong financial performance and stock growth, outperforming broader market indices and showing positive earnings results, indicating a favorable investment outlook. Group 1: Company Overview - Founded in 1901, Rollins, Inc. is based in Atlanta, Georgia, and provides pest and wildlife control services to both residential and commercial customers in the U.S. and internationally. The company has a market capitalization of $31.2 billion [1]. Group 2: Stock Performance - Rollins, Inc. shares have outperformed the broader market over the past year, with a stock price increase of 28.4% over the last 52 weeks and 7.2% year-to-date. In comparison, the S&P 500 Index has returned 15.6% over the past year and risen 1.7% in 2026 [2]. - The stock has also outperformed the Consumer Discretionary Select Sector SPDR ETF, which saw a 4.2% rise over the past 52 weeks and a 1.5% decline this year [3]. Group 3: Earnings Performance - On October 29, Rollins, Inc. stock rose by 7.3% following the release of its Q3 2025 earnings, which showed a 12% year-over-year revenue increase to $1 billion, surpassing analysts' estimates. The adjusted EPS was $0.35, beating Wall Street estimates by 9.4% [5]. - For the current year ending December 2025, analysts project a 15.2% year-over-year growth in EPS to $1.14 on a diluted basis. The company has a strong earnings surprise history, having surpassed or matched consensus estimates in each of the last four quarters [6]. Group 4: Analyst Ratings - Among the 15 analysts covering Rollins, Inc. stock, the consensus rating is a "Moderate Buy," consisting of nine "Strong Buy" ratings, two "Moderate Buys," and four "Holds," with this configuration remaining largely unchanged in recent months [6]. - UBS analyst Joshua Chan maintained a "Neutral" rating for Rollins stock and raised its price target from $61 to $65. The mean price target of $66.68 suggests a potential upside of 3.7% from current market prices, while the Street-high target of $72 indicates a possible rally of up to 12% [7].

Core Viewpoint - Procter & Gamble Company (NYSE: PG) has seen significant changes in institutional holdings, with some investors increasing their stakes while others, like Concord Asset Management, have reduced theirs by 19.4% in the third quarter. The company reported mixed financial results, with a slight year-over-year revenue increase and a dividend announcement. Group 1: Institutional Holdings - Concord Asset Management LLC VA reduced its holdings in Procter & Gamble by 19.4%, owning 17,452 shares worth $2,681,000 after selling 4,214 shares in the third quarter [2] - Other institutional investors have also modified their positions, with Halbert Hargrove Global Advisors LLC buying a new stake valued at approximately $25,000, and Manning & Napier Advisors LLC purchasing shares worth $44,000 [3] - Hedge funds and institutional investors collectively own 65.77% of Procter & Gamble's stock [3] Group 2: Financial Performance - Procter & Gamble reported earnings of $1.88 per share for the last quarter, exceeding analysts' expectations of $1.86 by $0.02, with revenue of $22.21 billion, slightly below the expected $22.36 billion [5] - The company achieved a net margin of 19.30% and a return on equity of 32.21%, with revenue up 1.5% year-over-year [5] - Procter & Gamble has set its FY 2026 EPS guidance at 6.830-7.090, with analysts expecting an EPS of 6.91 for the current fiscal year [5] Group 3: Dividend Information - Procter & Gamble announced a quarterly dividend of $1.0568 per share, to be paid on February 17th, with a record date of January 23rd, representing an annualized dividend of $4.23 and a yield of 2.7% [6] - The company's current payout ratio stands at 62.67% [6] Group 4: Stock Performance and Analyst Ratings - Procter & Gamble shares opened at $159.33, with a 52-week low of $137.62 and a high of $179.99, and a market capitalization of $370.28 billion [4] - Analysts have varied opinions on the stock, with BNP Paribas Exane reducing its target price from $172.00 to $164.00 while maintaining an "outperform" rating [8] - The consensus rating for Procter & Gamble is "Moderate Buy" with a target price of $167.67, with 13 analysts rating it as a Buy and 8 as Hold [8]

Company Overview - Eli Lilly and Company, based in Indianapolis, IN, is one of the world's largest pharmaceutical companies with a diversified product profile, including successful new drugs and a reliable pipeline in obesity, diabetes, and Alzheimer's [12]. Investment Potential - Eli Lilly is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of B, indicating a solid investment potential [12]. - The company is particularly appealing to growth investors, with a Growth Style Score of B, forecasting year-over-year earnings growth of 37.6% for the current fiscal year [13]. - In the last 60 days, five analysts have revised their earnings estimates higher for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.47 to $33.31 per share [13]. - Eli Lilly has an average earnings surprise of +8%, further enhancing its attractiveness to investors [13].